|
2025
|
Invention
|
Pyrimid-2-yl-pyrazole compounds as irak inhibitors.
Disclosed embodiments concern novel interleu... |
|
|
Invention
|
Treatment of cns tumors with olutasidenib and temozolomide. IDH1IDH1 mutations and for those with... |
|
|
Invention
|
Treatment of cns tumors with olutasidenib and temozolomide.
Provided are methods of treating a s... |
|
2024
|
Invention
|
Pyrazole compounds and method for making and using the compounds.
Disclosed embodiments concern ... |
|
|
Invention
|
Heterocyclic rip1 inhibitory compounds.
Disclosed herein are kinase inhibitory compounds, such a... |
|
|
Invention
|
Rip1 inhibitory compounds and methods for making and using the same.
Disclosed herein are kinase... |
|
|
Invention
|
Treatment of acute myeloid leukemia with olutasidenib, venetoclax and a hypomethylating agent. Pr... |
|
|
Invention
|
Dosage regimens for the treatment of autoimmune and inflammatory diseases using ly3871801. Disclo... |
|
|
Invention
|
Ret inhibitor for use in treating cancer having a ret alteration.
Disclosed herein are methods f... |
|
|
Invention
|
Use of a syk inhibitor for the treatment of chemical or radiation induced lung injury. Provided h... |
|
|
Invention
|
Use of a syk inhibitor for the treatment of sickle cell disease. Provided herein, among other thi... |
|
|
Invention
|
Inhibitors of ret.
Described herein are compounds that inhibit wild-type RET and its resistant m... |
|
2023
|
Invention
|
Pyrazole compounds, formulations thereof, and a method for using the compounds and/or formulation... |
|
|
Invention
|
Bicyclic inhibitors of irak.
Disclosed embodiments concern novel interleukin receptor associated... |
|
|
Invention
|
Bicyclic inhibitors of irak. Disclosed embodiments concern novel interleukin receptor associated ... |
|
|
Invention
|
Rip1k inhibitors. Disclosed herein are kinase inhibitory compounds, such as a receptor-interactin... |
|
|
Invention
|
Tricyclic irak inhibitors. Disclosed embodiments concern compounds according to Formula I In some... |
|
|
Invention
|
Tricyclic irak inhibitors.
Disclosed embodiments concern compounds according to Formula I
Disc... |
|
|
Invention
|
Pyrimid-2-yl-pyrazole compounds as irak inhibitors. Disclosed embodiments concern novel interleuk... |
|
|
P/S
|
Anti-cancer preparations; pharmaceutical products for the prevention and treatment of cancer; bio... |
|
|
P/S
|
Anti-cancer preparations; pharmaceutical products for the
prevention and treatment of cancer; bi... |
|
2022
|
Invention
|
Crystalline forms of a ripk1 inhibitor.
The present invention provides a crystalline compound of... |
|
|
Invention
|
Crystalline forms of a ripk1 inhibitor. The present invention provides a crystalline compound of ... |
|
|
Invention
|
2,4-diamino-pyrimidine compounds and method for making and using the compounds.
Compounds within... |
|
|
Invention
|
Amide compounds and method for making and using. Disclosed embodiments concern novel interleukin ... |
|
|
Invention
|
Tgf-β inhibitors. Disclosed are pyrazole compounds, as well as pharmaceutical compositions and me... |
|
|
Invention
|
Irak inhibitors and method for making and using. Disclosed embodiments concern interleukin recept... |
|
|
Invention
|
Heterocyclic rip1 kinase inhibitors. Disclosed herein are kinase inhibitory compounds, such as a ... |
|
|
Invention
|
Rip1 inhibitory compounds and methods for making and using the same. Disclosed herein are kinase ... |
|
|
Invention
|
Irak inhibitor for treating cytokine release-related conditions associated with infection by a re... |
|
|
Invention
|
Method for treatment of an excessive immunological response to an infection by a respiratory viru... |
|
|
Invention
|
Pyrazole compounds and methods for making and using the compounds.
Disclosed embodiments concern... |
|
|
Invention
|
Method for treating a disease or condition using a pyrazole compound or formulation thereof. Disc... |
|
|
Invention
|
A method for treating a disease or condition using a pyrazole compound or formulation thereof. Di... |
|
|
Invention
|
Compounds and method for treating cytokine release syndrome.
Disclosed herein are embodiments of... |
|
2021
|
Invention
|
Method of preparing pralsetinib.
Provided herein, in part, are compounds and compositions useful... |
|
|
P/S
|
Medical information services; Providing information services in the field of the treatment of med... |
|
|
Invention
|
Tyrosine kinase inhibitors. Disclosed are imidazole compounds, as well as pharmaceutical composit... |
|
|
Invention
|
Solid forms of pralsetinib. The compound cis)-N-((S)-1-(6-(4-fluoro-1H-pyrazol-1-yl)pyridin-3-yl)... |
|
|
Invention
|
Pralsetinib pharmaceutical compositions.
The present disclosure relates to pharmaceutical compos... |
|
|
P/S
|
Administration of financial assistance and reimbursement programs, namely, administration of fina... |
|
2020
|
P/S
|
Pharmaceutical and medical preparations; pharmaceutical preparations for the treatment of immune ... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of immune system diseases and disorders; pharmaceut... |
|
2019
|
P/S
|
Pharmaceutical preparations for the treatment of cancer |
|
|
P/S
|
Pharmaceutical preparations for the treatment of immune system diseases and disorders; Pharmaceut... |
|
2018
|
P/S
|
Pharmaceutical preparations for the treatment of cancer, auto-immune diseases, inflammatory disea... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer,
immune disorders, inflammation, rare di... |
|
|
P/S
|
pharmaceutical preparations for the treatment of cancer, immune disorders, inflammation, rare dis... |
|
|
P/S
|
Providing a database for collecting and reporting information pertaining to medical treatment, in... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of cancer, immune disorders, inflammation, rare dis... |
|
2017
|
P/S
|
Pharmaceutical preparations for the treatment of immune system diseases and disorders, namely, au... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of immune
system diseases and disorders; pharmaceu... |
|
|
P/S
|
Pharmaceutical preparations for the treatment of immunologic diseases, namely autoimmune diseases... |
|
2001
|
P/S
|
Pharmaceuticals for use in the treatment of [ viral diseases, ] cardiovascular and inflammatory d... |
|
1998
|
P/S
|
Pharmaceuticals for use in the treatment of viral diseases, cardiovascular and inflammatory disea... |
|
1997
|
P/S
|
Pharmaceutical for use in the treatment of viral diseases, cardiovascular and inflammatory diseas... |
|
|
P/S
|
research and development of technologies and scientific data in the field of new drug development... |
